Investment Management Corp of Ontario Has $3.77 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Investment Management Corp of Ontario increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,587 shares of the biopharmaceutical company’s stock after buying an additional 1,200 shares during the period. Investment Management Corp of Ontario’s holdings in Regeneron Pharmaceuticals were worth $3,771,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after purchasing an additional 96,266 shares during the period. TD Asset Management Inc increased its position in Regeneron Pharmaceuticals by 30.4% during the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock worth $369,484,000 after buying an additional 82,034 shares during the last quarter. Icon Wealth Advisors LLC raised its stake in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after buying an additional 75,569 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Regeneron Pharmaceuticals by 86.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 144,865 shares of the biopharmaceutical company’s stock valued at $152,257,000 after buying an additional 67,235 shares during the period. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on REGN shares. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Finally, Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,107.29.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ REGN opened at $749.57 on Wednesday. The stock has a market capitalization of $82.37 billion, a P/E ratio of 18.55, a PEG ratio of 2.94 and a beta of 0.08. The stock’s fifty day moving average is $893.12 and its 200 day moving average is $1,016.56. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.